Sanofi’s eczema drug gets EU approval to treat adolescentsThe European Commission (EC) has extended the marketing authorisation for Sanofi and Regeneron’s eczema drug Dupixent (dupilumab) to Share XSanofi’s eczema drug gets EU approval to treat adolescentshttps://pharmaphorum.com/news/sanofi-eczema-drug-gets-eu-approval-adolescents/
Almirall gets in on the eczema actionSanofi’s Dupixent has shown there is a market for biologic drugs to treat eczema, and now Spain’s Almirall Share XAlmirall gets in on the eczema actionhttps://pharmaphorum.com/views-analysis-market-access/almirall-gets-in-on-the-eczema-action/
Sanofi ups revenues forecasts as eczema drug Dupixent surgesSanofi has upped its revenue forecasts for the year on the back of strong second quarter results from Share XSanofi ups revenues forecasts as eczema drug Dupixent surgeshttps://pharmaphorum.com/news/sanofi-ups-revenues-forecasts-as-eczema-drug-dupixent-surges/
Sanofi licenses OTC Tamiflu rights for the US marketSanofi has made a bold play to bolster its consumer health business, licensing non-prescription rights to Roche’s influenza Share XSanofi licenses OTC Tamiflu rights for the US markethttps://pharmaphorum.com/news/sanofi-licenses-otc-tamiflu-rights-for-the-us-market/
German court blocks Sanofi’s cholesterol drug after Amgen lawsuitAmgen has lived up to its litigious reputation after it successfully persuaded a German court to uphold a Share XGerman court blocks Sanofi’s cholesterol drug after Amgen lawsuithttps://pharmaphorum.com/news/german-court-blocks-sanofis-cholesterol-drug-after-amgen-lawsuit/
GSK hires former Genentech expert for AI unitGlaxoSmithKline has hired computational drug design specialist Dr Kim Branson to expand its artificial intelligence and machine learning Share XGSK hires former Genentech expert for AI unithttps://pharmaphorum.com/news/gsk-hires-former-genentech-expert-for-ai-unit/
FDA reviews Sanofi’s multiple myeloma drug isatuximabThe FDA has begun its review of Sanofi’s multiple myeloma drug isatuximab, as the French pharma prepares for Share XFDA reviews Sanofi’s multiple myeloma drug isatuximabhttps://pharmaphorum.com/news/fda-reviews-sanofis-multiple-myeloma-drug-isatuximab/
Immediately after EU nod, England’s NHS funds Sanofi skin cancer drugPatients in England will be among those who are first to benefit from Sanofi and Regeneron’s new cancer Share XImmediately after EU nod, England’s NHS funds Sanofi skin cancer drughttps://pharmaphorum.com/news/immediately-after-eu-nod-englands-nhs-funds-sanofi-skin-cancer-drug/
Almirall takes option on Dermira’s eczema drug lebrikizumabSpain’s Almirall has taken an option granting rights to develop and market Dermira’s eczema drug lebrikizumab in Europe, Share XAlmirall takes option on Dermira’s eczema drug lebrikizumabhttps://pharmaphorum.com/news/almirall-takes-option-on-dermiras-eczema-drug-lebrikizumab/
